Abstract #1113

Radiomic Analysis Differentiates between True Progression and Pseudo-progression in Glioblastoma patients: A Large Scale Multi-institutional Study

Aikaterini Kotrotsou¹, Srishti Abrol¹, Nabil A Elshafeey¹, Islam Hassan¹, Dunia Giniebra Camejo², Ahmed Hassan¹, Tagwa Idris¹, Ahmed Salem¹, Kamel El Salek¹, Ahmed Elakkad¹, Kristin D Alfaro-Munoz³, Shiao-Pei Weathers³, Fanny E Moron⁴, John F deGroot³, Meng Law⁵, Pascal O Zinn⁶, and Rivka R Colen^1,2

¹Diagnostic Radiology, MD Anderson Cancer Center, Houston, TX, United States, ²Cancer Systems Imaging, MD Anderson Cancer Center, Houston, TX, United States, ³Neuro-Oncology, MD Anderson Cancer Center, Houston, TX, United States, ⁴Neuroradiology, Baylor College of Medicine, Houston, TX, United States, ⁵Neuroradiology, University of Southern California Keck Medical Center, Los Angeles, CA, United States, ⁶Neurosurgery, Baylor College of Medicine, Houston, TX, United States

The benign treatment-related imaging changes may pose a challenge in appropriate clinical decision making for the neuro-oncologists. The post-treatment changes are usually benign and differ largely in management approach from a progressive tumor. In this study, 304 glioblastoma patients were evaluated retrospectively to study the ability of radiomic analysis to distinguish the post-treatment changes from a truly progressive disease. 3D volumetrics using 3D Slicer 4.3.1 and texture analysis of the lesions were performed. On LOOCV, sensitivity and specificity of 97% and 72% were obtained respectively. We concluded that radiomics can differentiate between the progressive disease and pseudo-progression in glioblastoma patients.

This abstract and the presentation materials are available to members only; a login is required.

Join Here